Evidence map›Paper›PMID 33843575›Full record

ArticleThe Journal of general virology2021

The infectivity of progeny adenovirus in the presence of neutralizing antibody.

Takamasa Hirai, Anna Sato, Naoya Koizumi, Yoh Kurioka, Yui Suzuki, Junpei Kano, Makie Yamakawa, Tetsuya Nomura, Makiko Fujii, Fuminori Sakurai and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of general virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Takamasa HiraiDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Anna SatoDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Naoya KoizumiDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Yoh KuriokaDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Yui SuzukiDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Junpei KanoDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Makie YamakawaDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Tetsuya NomuraDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.
Makiko FujiiLaboratory of Physical Chemistry, School of Pharmacy, Nihon University, Chiba, Japan.
Fuminori SakuraiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Hiroyuki MizuguchiLaboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Yoshiteru WatanabeDepartment of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
Naoki UtoguchiDepartment of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adenoviruses (Ads), common pathogens that cause upper respiratory and gastrointestinal infections, are blocked by neutralizing antibodies (nAbs). However, Ads are not fully eliminated even in hosts with nAbs. In this study, we assessed the infectivity of progeny Ad serotype 5 (Ad5) in the presence of nAb. The infectivity of Ad5 was evaluated according to the expression of the Ad genome and reporter gene. Infection by wild-type Ad5 and Ad5 vector continued to increase until 3 days after infection even in the presence of nAb. We established an assay for determining the infection levels of progeny Ad5 using a sorting system with magnetic beads and observed little difference in progeny Ad5 counts in the presence and absence of nAb 1 day after infection. Moreover, progeny Ad5 in the presence of nAb more effectively infected coxsackievirus and adenovirus receptor (CAR)-positive cells than CAR-negative cells. We investigated the function of fiber proteins, which are the binding partners of CAR, during secondary infection, observing that fibre proteins spread from infected cells to adjacent cells in a CAR-dependent manner. In conclusion, this study revealed that progeny Ad5 could infect cells even in the presence of nAb, differing from the common features of the Ad5 infection cycle. Our findings may be useful for developing new therapeutic agents against Ad infection.

Indexed as

Adenoviruses, HumanAdenovirus Infections, HumanAntibodies, NeutralizingGenes, ReporterGenetic VectorsHEK293 CellsHumansVirulenceAntibodies, Neutralizingadenovirusfibre proteinimmune evasionneutralizing antibody

Identifiers

PMID33843575
PMCPMC8290266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.